Pharmaceutical composition for preventing and treating periodontal diseases, comprising alnus japonica sp. plant extract as active ingredient, food composition for alleviating periodontal diseases, comprising same, and toothpaste and feed comprising same

Abstract

A pharmaceutical composition for preventing and treating periodontal diseases, comprising an Alnus japonica sp. plant extract as an active ingredient is provided. The Alnus japonica sp. plant extract according to the present invention comprises oregonin or a non-saccharide thereof, and thus has excellent effects of alleviating, preventing and treating periodontal diseases.

Description

Pharmaceutical composition for preventing and treating periodontal disease containing extract of the plant of the genus Alder as an active ingredient, food composition for improving periodontal disease containing the same, toothpaste and feed containing the same

[0001] The present invention relates to a pharmaceutical composition for preventing and treating periodontal disease containing an extract of a plant of the genus Alder as an active ingredient, a food composition for improving periodontal disease containing the same, and a toothpaste and feed containing the same.

[0002] Periodontal disease refers to all diseases that occur in the periodontal tissue, and is divided into gingivitis and periodontitis depending on the severity of the disease. Gingivitis is a relatively mild and quickly curable form of periodontal disease, where inflammation is limited to the gums and soft tissues, while periodontitis refers to cases where the inflammation has progressed to the gums and the surrounding gum bone. Periodontal disease is not only a major cause of tooth loss after middle age, but also has a strong correlation with systemic diseases such as dementia, arteriosclerosis, myocardial infarction, and stroke. Therefore, interest in the prevention and treatment of periodontal disease is increasing in modern society, which has entered an aging society.

[0003] Alnus spp., a genus of plants belonging to the birch family (Betulaceae), is distributed throughout the Northern Hemisphere, including Korea, the United States, Japan, and China. Seventeen species, including Alnus japonica Steudel, are known to grow natively in Korea (1, 2). The most characteristic compound of Alnus plants is a diarylheptanoid series compound, and many researchers have discovered that this compound exists in Alnus plants. There have been numerous reports on determining the structure of oregonine, a diarylheptanoid glycoside, by tracking the substance that turns reddish brown when cutting trees of the genus Alder (A. rubura, A. hirsuta, A. japonica). In addition, many studies have been reported by researchers around the world on chemical phylogenetic studies of plants of the genus Alder using oregonine as an indicator substance (see Patent Document 0001) Korean Patent Publication No. 10-2009-0061128, (Patent Document 0002) Korean Patent Registration No. 10-1756020, (Patent Document 0003) Korean Patent Publication No. 10-2018-0085636, (Patent Document 0004) Korean Patent Registration No. 10-2217551).

[0004] However, there has been no specific report yet on the preventive and therapeutic properties of extracts of the genus Oryzae and its effective substances for periodontal diseases such as gingivitis.

[0005] Therefore, the problem that the present invention seeks to solve is to provide a substance that prevents, treats, or improves periodontal disease.

[0006] In order to solve the above problem, the present invention provides a pharmaceutical composition for preventing and treating periodontal disease, which contains an extract of the Alnus plant as an active ingredient.

[0007] In one embodiment of the present invention, the extract of the plant of the genus Oryzae comprises any one of the following compounds.

[0008] [Chemical Formula 1]

[0009]

[0010] [Chemical Formula 2]

[0011]

[0012] [Chemical Formula 3]

[0013]

[0014]

[0015] In one embodiment of the present invention, the chemical formulas 2 and 2 are obtained by enzymatic decomposition of the extract of the plant of the genus Ornithine.

[0016] In one embodiment of the present invention, the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

[0017] The present invention provides a food composition for preventing and improving periodontal disease, comprising an extract of the Ulmus genus as an active ingredient.

[0018] In one embodiment of the present invention, the extract of the plant of the genus Oryzae comprises any one of the following compounds.

[0019] [Chemical Formula 1]

[0020]

[0021] [Chemical Formula 2]

[0022]

[0023] [Chemical Formula 3]

[0024]

[0025] In one embodiment of the present invention, the chemical formulas 2 and 2 are obtained by enzymatic decomposition of the extract of the plant of the genus Ornithine.

[0026] In one embodiment of the present invention, the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

[0027] The present invention also provides a toothpaste or oral cleanser composition comprising an Ulmus plant extract as an active ingredient.

[0028] In one embodiment of the present invention, the extract of the plant of the genus Oryzae comprises any one of the following compounds.

[0029] [Chemical Formula 1]

[0030]

[0031] [Chemical Formula 2]

[0032]

[0033] [Chemical Formula 3]

[0034]

[0035]

[0036] In one embodiment of the present invention, the chemical formulas 2 and 2 are obtained by enzymatic decomposition of the extract of the plant of the genus Ornithine.

[0037] In one embodiment of the present invention, the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

[0038] The present invention also provides a feed containing an extract of the Ulmus plant as an effective ingredient.

[0039] In one embodiment of the present invention, the extract of the plant of the genus Oryzae comprises any one of the following compounds.

[0040] [Chemical Formula 1]

[0041]

[0042] [Chemical Formula 2]

[0043]

[0044] [Chemical Formula 3]

[0045]

[0046]

[0047] In one embodiment of the present invention, the chemical formulas 2 and 2 are obtained by enzymatic decomposition of the extract of the plant of the genus Ornithine.

[0048] In one embodiment of the present invention, the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

[0049] A pharmaceutical composition or food composition for preventing and treating periodontal disease comprising an extract of the genus Oryzae according to the present invention as an active ingredient has excellent effects of improving, preventing and treating periodontal disease by including oregonine or its aglycone.

[0050] Figures 1 to 3 illustrate an extraction method for obtaining an extract of a maple tree according to one embodiment of the present invention.

[0051] Figure 4 is a step diagram of a method for obtaining a composite extract of king pine and elm according to one embodiment of the present invention.

[0052] Figure 5 shows the TLC analysis results for the extract obtained above.

[0053] Figure 6 shows the results of TLC monitoring to determine changes in components when enzyme decomposed.

[0054] Figure 7 shows the calibration curve results for oregonine.

[0055] Figures 8 to 10 show the HPLC analysis results of oregonine components for extracts AJ60E, AJRF1, and AJRF2, respectively.

[0056] Figures 11 to 13 show the HPLC analysis results of the components Hirsutanonol and Hirsutenone in extracts AJ60E, AJRF1, and AJRF2, respectively.

[0057] Figure 14 shows the results of TNFα expression analysis when treated with each extract.

[0058] Figure 15 shows the results of the analysis of IL-6 expression levels when treated with each extract.

[0059] Figure 16 shows the results of analysis of IL-1β expression when treated with each extract.

[0060] Hereinafter, specific embodiments of the present invention will be described with reference to the drawings. However, these are merely examples and the present invention is not limited thereto.

[0061] In describing the present invention, detailed descriptions of known technologies related to the present invention will be omitted if they are deemed to unnecessarily obscure the gist of the invention. Furthermore, the terms described below are defined based on their functions within the present invention and may vary depending on the intent or custom of the user or operator. Therefore, their definitions should be based on the overall content of this specification.

[0062] The technical idea of ​​the present invention is determined by the claims, and the following examples are merely a means of efficiently explaining the technical idea of ​​the present invention to a person having ordinary skill in the technical field to which the present invention belongs.

[0063] In the present invention, the solvent extraction process can partially or completely remove the extraction solvent through filtration, concentration, or drying after the extract is prepared. Partial removal refers to concentration until an aqueous concentrate free of a significant amount of organic solvent is obtained, while complete removal can result in a dry residue. For example, filtration can be performed using filter paper or a vacuum filtration device, concentration can be performed using a vacuum condenser, and drying can be performed using a freeze-drying method, but these are not limited thereto.

[0064] The term "extract" in the present invention has the meaning commonly used in this technical field as a crude extract as described above, but in a broader sense, it also includes a fraction obtained by further fractionating the crude extract. The fractionation using the solvent may be performed through an additional extraction process using the solvent.

[0065] The term “comprising as an active ingredient” in this specification means that the extract of the present invention is contained in an amount sufficient to achieve the efficacy of preventing and treating muscle loss.

[0066] In this specification, the term “periodontal disease” means any disease occurring in periodontal tissue, and the term “prevention” used in the present invention means any act of suppressing or delaying the onset of periodontal disease by administering the pharmaceutical composition according to the present invention. In addition, the term “treatment” used in the present invention means any act of improving or beneficially changing the symptoms of periodontal disease by administering the pharmaceutical composition according to the present invention. The term “improvement” used in the present invention means any act of at least reducing a parameter related to the condition being treated, for example, the degree of symptoms. At this time, the functional food composition may be used simultaneously with or separately from a drug for treatment before or after the onset stage of the disease in order to prevent or improve periodontal disease.

[0067] The pharmaceutical composition for preventing and treating periodontal disease of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent.

[0068] Pharmaceutically acceptable carriers in the composition of the present invention are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweetening agents, flavoring agents, emulsifiers, suspending agents, preservatives, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0069] The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc.

[0070] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a generally skilled physician can easily determine and prescribe a dosage effective for the desired treatment or prevention.

[0071] The pharmaceutical composition for preventing and treating periodontal disease of the present invention may contain other pharmaceutically active ingredients in addition to the extract of the plant of the genus Alder as an active ingredient, or may be used in combination with a pharmaceutical composition containing other active ingredients.

[0072] The food or health functional food composition of the present invention may further include a food additive that is acceptable from a food science perspective. The food additive that is acceptable from a food science perspective that may be used in the present invention includes, but is not limited to, natural carbohydrates such as sugars such as glucose, fructose, maltose, sucrose, dextrin, and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol, natural flavoring agents such as thaumatin and stevia extract, synthetic flavoring agents such as saccharin and aspartic acid, coloring agents, pectic acid or its salt, alginic acid or its salt, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonating agents. The food composition of the present invention may be in a form selected from the group consisting of powder, granules, tablets, capsules, candy, chewing gum, jelly, and beverage. The content of the extract of the genus Alder in the above food composition may be appropriately selected in consideration of the shape, flavor, taste, etc. of the food, and may range, for example, from 0.01 to 30 wt% based on the total weight of the food. It will be apparent to those skilled in the art that the shape, composition, manufacturing method, etc. of the food composition according to the present invention may be appropriately selected from conventional techniques known in the art.

[0073] In order to solve the above-described problem, the present invention provides a pharmaceutical composition for preventing and treating periodontal disease containing an extract of a plant of the genus Alder as an active ingredient, and a health functional food for improving periodontal disease containing the same, the manufacturing method of which is as follows.

[0074] Example 1

[0075] Figures 1 to 3 are step diagrams of an extraction method for obtaining an extract of a maple tree according to one embodiment of the present invention.

[0076] Referring to Figure 1, 8 kg of branches including alder bark were extracted using 60% ethanol at room temperature for 3 to 5 days. After extraction, the product was filtered through filter paper (hdmicro, No. 20) and concentrated under reduced pressure. After concentration was completed, the product was freeze-dried in a freeze dryer for 3 days and 483.31 g (AJ60E) of the product was recovered.

[0077] Afterwards, solvent fractionation is performed, as shown in Fig. 2.

[0078] Referring to Fig. 2, 200 g of the obtained product (AJ60E) was dissolved in 1 L of distilled water per 5 g, filtered through filter paper, and solvent fractionation was performed with the AJ60E diluted solution and ethyl acetate in a ratio of 1:1.5. Thereafter, the ethyl acetate (EA) layer and the water layer were secured, concentrated using a vacuum concentrator, and 74.39 g was recovered after lyophilization. The EA extract obtained at this time is AJRF1, a high-content extract derived from alder trees.

[0079] Fig. 3 is a step diagram for enzymatic decomposition of AJ60E obtained in Fig. 1, unlike Fig. 2.

[0080] Referring to Fig. 3, 20 g of J60E was dissolved in 850 ml of distilled water, 75 ml of each enzyme was added, and the mixture was stirred at approximately 55 degrees Celsius for 24 hours. The enzymes used were PectinexUltra SP-L and PectinexUltra Pulp / Novozymes.

[0081] After 24 hours, the enzyme was inactivated by heating, and centrifugation was performed at 10,000 rpm, 15 min, 4℃ using a centrifuge. After that, the supernatant was obtained using filter paper, and the supernatant and ethyl acetate were mixed in a 1:1 ratio, and solvent fractionation was performed using a separatory funnel. After that, the EA layer was recovered using filter paper, and the aqueous layer was solvent fractionated again with new EA to secure about 2 L of EA layer. After that, a total of 89 g (AJRF2) of the alder extract obtained by enzyme decomposition was obtained by concentration under reduced pressure.

[0082]

[0083] Example 2

[0084] Figure 4 is a step diagram of a method for obtaining a composite extract of king pine and elm according to one embodiment of the present invention.

[0085] Referring to Fig. 4, for the extraction of the complex extract of the Korean maple and the elm, 150 kg each of Korean maple and the elm were mixed in a 1:1 ratio. 3,000 kg (1:10, w / w) of 50% alcohol was mixed with 300 kg of the prepared raw material, and extraction was performed for 6 hours at 75 ± 5℃. After the extraction was completed, it was cooled to room temperature, filtered through a 0.2 μm filter, and concentrated under reduced pressure to 60 Brix (55 ± 5℃, 60 bar) to obtain the complex extract of the Korean maple and the elm (E50) (Lot. No. DJTH-06466). After the concentration was completed, dextrin and purified water were mixed based on the concentrate, and freeze-drying was performed. After freeze-drying, 30 kg of extract powder of the King Oryza sativa (E50) (Lot. No. DJTH-06465) was recovered.

[0086]

[0087] Experimental example

[0088] TLC analysis

[0089] TLC monitoring was performed to determine the presence or absence of oregonine components. At this time, the TLC plate was a sillicagel plate, and the developing solvent was CMW (chloroform: methanol: water = 70:30:4), and a UV detector and 10% H2SO4, p-Anisaldehyde H2SO 4, Experiments were conducted using a chromogenic reagent such as FeCl3.

[0090] Figure 5 shows the TLC analysis results for the extract obtained above.

[0091] Referring to Figure 5, when comparing the Rf values ​​of oregonine and each sample from the TLC monitoring experiment results, spots and colors were confirmed in the same location as oregonine in all samples. This allows for qualitative confirmation that oregonine contains the active ingredient in each sample.

[0092] In particular, the enzyme-decomposed AJRF2 showed faint color development in the spot of oregonine, a glycoside compound of the following chemical formula 1, and the presence of various non-glycoside compounds, including Hirsutanonol of the following chemical formula 2 and Hirstenone of the following chemical formula 3, which are non-glycoside compounds, was clearly confirmed as spots, indicating a clear conversion from a glycoside to an non-glycoside compound.

[0093] [Chemical Formula 1]

[0094]

[0095] [Chemical Formula 2]

[0096]

[0097] [Chemical Formula 3]

[0098]

[0099]

[0100] Figure 6 shows the results of TLC monitoring to identify changes in components after enzymatic decomposition. Here, a UV detector and 10% H2SO4, p-Anisaldehyde H2SO 4, Experiments were conducted using a chromogenic reagent such as FeCl3, and when comparing AJ60E and AJRF1 with AJRF2, the characteristic of the AJRF2 sample was that oregonin was deglycosylated by enzymatic decomposition and converted to an aglycone, and the darkly colored oregonin spot became lighter while the aglycone spot became darker. This was confirmed through a qualitative confirmation test method.

[0101]

[0102] HPLC quantitative analysis

[0103] To confirm the content of effective substances in each sample, HPLC quantitative analysis was performed. Samples were dissolved in MeoH for HPLC to prepare 1,000 ppm samples, and analysis was performed using Waters 2695 Separation module and 2487 Dual λ Absorbance Detector, using 1% Acetic acid and ACN as the mobile phase. Analysis was performed for 40 minutes to secure a calibration curve for effective substances (see Figure 7), and a chromatogram was obtained at a wavelength of 280 nm.

[0104] Figures 8 to 10 show the HPLC analysis results of oregonine components for extracts AJ60E, AJRF1, and AJRF2, respectively.

[0105] Referring to Figures 8 to 10, it was confirmed that the effective substance oregonin was contained in each 1,000 ppm of the extract sample (AJ 60E: 238.22 ppm), (AJRF1: 583.59 ppm), and AJRF2 (ND), respectively.

[0106] As a result of analyzing oregonin in solvent-fractionated AJRF1, it was confirmed that the oregonin content increased by approximately 244% compared to AJ60E.

[0107] In the case of enzymatically degraded AJRF2, the oregonin content decreased as oregonin lost sugar due to enzymatic decomposition, and it was confirmed that the Oregonin content was reduced by more than 94% compared to AJ60E.

[0108] Figures 11 to 13 show the HPLC analysis results of the components Hirsutanonol and Hirsutenone in extracts AJ60E, AJRF1, and AJRF2, respectively.

[0109] Referring to Figures 11 to 13, the content of non-glycosides was very low in AJ60E and AJRF1 before enzymatic degradation, making it difficult to confirm, but in the case of AJRF2, oregonin was decomposed into sugar by enzymatic degradation, and the oregonin content decreased by more than 94% compared to AJ60E, and the peaks of the non-glycosides produced as a result, Hirsutanonol and Hirsutenone, were confirmed at 16.261 min and 23.013 min, respectively, and 247.70 ppm of Hirsutanonol and 314.33 ppm of Hirsutenone were confirmed, respectively. As a result, it can be confirmed that Hirsutanonol increased by 247.70% and Hirsutenone increased by 314.33%.

[0110]

[0111] Effective in improving periodontal disease

[0112] In this experimental example, in order to confirm the treatment and improvement effect of periodontal disease, an inflammatory environment creation model for periodontal disease was first constructed according to the following method.

[0113]

[0114] 1) Analysis of intracellular inflammatory cytokine expression levels

[0115] - Model of creating an endogenous inflammatory environment

[0116] ① 1 x 10 gingival fibroblasts in a 12-well plate 5 / Dispense at a density of 100 ml and culture for 12 hours.

[0117] ② Additional culture after treatment with 10 ng / ml of TNFα and a defined concentration of test substance.

[0118] ③ Extract RNA from cultured cells using a total RNA extraction kit.

[0119] ④ Synthesize cDNA using a reverse transcription kit.

[0120] ⑤ Quantitative RT-PCR is performed using SYBR reagent, and Ct (cycle threshold) values ​​are derived using specific primers for three types of pro-inflammatory cytokines (TNFα, IL-6, IL-1β, etc.).

[0121] ⑥ Analyze the relative expression level of pro-inflammatory cytokines using the △△Ct method.

[0122] -Exogenous inflammatory environment creation model

[0123] ① 1 x 10 gingival fibroblasts in a 12-well plate 5 / Dispense at a density of 100 ml and culture for 12 hours.

[0124] ② Additional culture after treatment with LPS (1 ug / ml) or extracellular vesicles derived from oral bacteria (e.g., Porphyromonas gingivalis) and a specified concentration of test substance.

[0125] ③ Extract RNA from cultured cells using a total RNA extraction kit.

[0126] ④ Synthesize cDNA using a reverse transcription kit.

[0127] ⑤ Quantitative RT-PCR is performed using SYBR reagent, and Ct (cycle threshold) values ​​are derived using specific primers for three types of pro-inflammatory cytokines (TNFα, IL-6, IL-1β, etc.).

[0128] ⑥ Analyze the relative expression level of pro-inflammatory cytokines using the △△Ct method.

[0129]

[0130] 2) Evaluation of intracellular inflammatory signaling molecular mechanisms

[0131] - Model of creating an endogenous inflammatory environment

[0132] ① 1 x 10 gingival fibroblasts in a 12-well plate 5 / Dispense at a density of 100 ml and culture for 12 hours.

[0133] ② Additional culture after treatment with 10 ng / ml of TNFα and a defined concentration of test substance.

[0134] ③ After disrupting the cells with Laemmli sample buffer, sonication and heating at 95 ℃ for 5 minutes were used to extract total proteins from cultured cells.

[0135] ④ After performing SDS-PAGE, transfer the protein to a PVDF membrane and block the membrane by immersing it in 5% skim milk for 30 minutes.

[0136] ⑤ After binding phospho NFκB, phospho STAT3, total NFκB, and total STAT3 specific antibodies, chemiluminescence signals were detected and quantified.

[0137]

[0138] - Model of creating an exogenous inflammatory environment

[0139] ① 1 x 10 gingival fibroblasts in a 12-well plate5 / Dispense at a density of 100 ml and culture for 12 hours.

[0140] ② Additional culture after treatment with LPS (1 ug / ml) or extracellular vesicles derived from oral bacteria (e.g., Porphyromonas gingivalis) and a specified concentration of test substance.

[0141] ③ After disrupting the cells with Laemmli sample buffer, sonication and heating at 95 ℃ for 5 minutes were used to extract total proteins from cultured cells.

[0142] ④ After performing SDS-PAGE, transfer the protein to a PVDF membrane and block the membrane by immersing it in 5% skim milk for 30 minutes.

[0143] ⑤ After binding phospho NFκB, phospho STAT3, total NFκB, and total STAT3 specific antibodies, chemiluminescence signals were detected and quantified.

[0144] The anti-inflammatory effect of fibroblasts in the model constructed according to the above method was analyzed as follows.

[0145] Figure 14 shows the results of TNFα expression analysis.

[0146] Referring to Figure 14, it can be confirmed that all samples containing oregonin, a glycoside compound derived from alder, and hirsutanonol and hirsutenone, a non-glycoside compound, statistically significantly strongly inhibit TNFα expression. This result is judged to contribute to aggravating symptoms and blocking immunological chain reactions in inflammatory diseases. In addition, it can be confirmed that the elm and alder complex extract (UM / A 50E) also statistically significantly strongly inhibits TNFα expression due to the presence of oregonin, a glycoside compound of alder.

[0147] Figure 15 shows the results of IL-6 expression analysis.

[0148] Referring to Figure 15, it can be confirmed that all samples containing oregonin, a glycoside compound derived from the alder tree, and hirsutanonol and hirsutenone, a non-glycoside compound, statistically significantly strongly inhibited IL-6 expression.

[0149] In addition, the AJ60E extract has an oregonin content of 238.22 ug / ml, and AJRF1 has an oregonin content of 583.59 ug / ml, which is a high-content extract with 244.98% more oregonin than AJ60E. What can be confirmed from the results of this experiment is that the higher the Oregonin content, the more strongly it suppresses IL-6 expression.

[0150] Furthermore, the enzymatic hydrolysate, which produces a high content of aglycone compounds with significantly increased aglycone compounds, contains hirsutanonol and hirsutenone, which are representative aglycone compounds that can be produced from oregonin through enzymatic hydrolysis from oregonin, a glycoside compound well known as an indicator and effective substance of the alder tree, and it was confirmed that AJRF2, which contains hirsutanonol and hirsutenone, is the most potent inhibitor of IL-6 expression among the extracts produced from the alder tree.

[0151] It was confirmed that the elm and alder complex extract (UM / A 50E) also strongly inhibited IL-6 expression with statistical significance because it contained oregonin, an alder glycoside compound.

[0152] Figure 16 shows the results of analysis of IL-1β expression.

[0153] Referring to Figure 16, it can be confirmed that all samples containing oregonane, a glycoside compound derived from the alder tree, and the non-glycoside compounds hirsutanonol and hirsutenone very strongly inhibited IL-1β expression with statistical significance.

[0154] In particular, it is expected that it can be applied in future immune-related disease and inflammatory disease models by regulating the expression of IL-1β, a representative compound of inflammatory cytokines. It was also confirmed that the elm and alder complex extract (UM / A 50E) strongly inhibits IL-1β expression with statistical significance as it contains oregonin, an alder glycoside compound.

[0155] As described above, the pharmaceutical composition or food composition for preventing and treating periodontal disease containing the extract of the plant of the genus Oryzae according to the present invention as an active ingredient has excellent effects of improving, preventing and treating periodontal disease by containing oregonine or its aglycone.

[0156] Therefore, the composition containing the extract of the plant of the genus Olive according to the present invention as an active ingredient can be used as an ingredient of toothpaste or oral cleanser for humans and animals in addition to a pharmaceutical composition or a food composition, and can further be used as feed for animals such as companion animals.

[0157] The composition according to the present invention has industrial applicability as a therapeutic agent, etc.

Claims

1. A pharmaceutical composition for preventing and treating periodontal disease, comprising an extract of the Alnus plant as an active ingredient.

2. In paragraph 1, A pharmaceutical composition for preventing and treating periodontal disease, characterized in that the above-mentioned extract of the plant of the genus Oryza sativa contains any one of the following compounds. [Chemical Formula 1] [Chemical Formula 2] [Chemical Formula 3] 3. In paragraph 2, The above chemical formulas 2 and 2 are pharmaceutical compositions for preventing and treating periodontal disease, characterized in that they are obtained by enzymatic decomposition of the extract of the genus Ornithine.

4. In any one of paragraphs 1 to 3, A pharmaceutical composition for preventing and treating periodontal disease, characterized in that the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

5. A food composition for preventing and improving periodontal disease, comprising an extract of the Ulmus genus as an active ingredient.

6. In paragraph 5, A food composition for preventing and improving periodontal disease, characterized in that the above-mentioned extract of the plant of the genus Oryza sativa contains any one of the following compounds. [Chemical Formula 1] [Chemical Formula 2] [Chemical Formula 3] 7. In paragraph 6, A food composition for preventing and improving periodontal disease, characterized in that the above chemical formulas 2 and 2 are obtained by enzymatic decomposition of the extract of the genus Ornithine.

8. In any one of paragraphs 5 to 7, A food composition for preventing and improving periodontal disease, characterized in that the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

9. A toothpaste composition containing an extract of the Ulmus genus as an active ingredient.

10. In paragraph 9, A toothpaste or oral cleanser composition, characterized in that the above-mentioned extract of the plant of the genus Oryza sativa contains any one of the following compounds. [Chemical Formula 1] [Chemical Formula 2] [Chemical Formula 3] 11. In paragraph 10, A toothpaste or oral cleanser composition characterized in that the above chemical formulas 2 and 2 are obtained by enzymatic decomposition of the extract of the above Oryza sativa plant.

12. In any one of paragraphs 9 to 11, A toothpaste or oral cleanser composition characterized in that the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

13. Feed containing Ulmus plant extract as an active ingredient.

14. In paragraph 13, A feed characterized in that the above-mentioned extract of the plant of the genus Oryza sativa contains any one of the following compounds. [Chemical Formula 1] [Chemical Formula 2] [Chemical Formula 3] 15. In paragraph 14, The above chemical formulas 2 and 2 are feeds characterized in that they are obtained by enzymatic decomposition of the extract of the above Oryza sativa plant.

16. In any one of paragraphs 13 to 15, A feed characterized in that the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

Images